At the recent year-end call Allos Therapeutics (NASDAQ: ALTH) reported financial and developmental 2007 highlights. As-of 31 December the company had a cash and cash equivalent position of $57.8M on hand, the coffers were achieved primarily via a 1Q07 9M common share offering that raised just north of $50M. With a quarterly burn of approximately [...]